Zobrazeno 1 - 10
of 66
pro vyhledávání: '"C Hielscher"'
Autor:
Stephen Everse, Abigail C. Hielscher
Publikováno v:
MedEdPublish, Vol 12 (2023)
Background: Peer teaching is a powerful educational tool utilized in medical school curricula. Previously, first year medical students taught their peers about the gross anatomical structures they had dissected in the anatomy lab. While this strategy
Externí odkaz:
https://doaj.org/article/919d866bdfea4d649dc74039691d016c
Autor:
Abigail C. Hielscher, Stephen Everse
Publikováno v:
MedEdPublish. 12:48
Background: Peer teaching is a powerful educational tool utilized in medical school curricula. Previously, first year medical students taught their peers about the gross anatomical structures they had dissected in the anatomy lab. While this strategy
Autor:
Abby C. Hielscher
Publikováno v:
The FASEB Journal. 36
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Friedrich Overkamp, Sara Y. Brucker, A Abenhardt, Andreas D. Hartkopf, J Lermann, P. Hadji, PA Fasching, Lothar Haeberle, Wolfgang Janni, Hans Tesch, Jens Huober, Volkmar Müller, C Thomssen, C Hielscher, H-C Kolberg, D. Wallwiener, Andreas Schneeweiss, F-A Taran, Markus Wallwiener, D Lüftner, M. W. Beckmann, MP Lux, Erik Belleville, P Wimberger, Bernhard Volz, Johannes Ettl, Christian M. Kurbacher, Michael Untch, Tanja Fehm, M Geberth, Rachel Wuerstlein
Publikováno v:
Cancer Research. 79:OT1-11
Background During the last decades the treatment of advanced breast cancer (ABC) patients has improved due to a variety of new treatment strategies. Nevertheless, many ABC patients are faced with limited prognosis, and their treatment remains a chall
Autor:
Sara Y. Brucker, P. Hadji, L Haeberle, F-A Taran, Erik Belleville, AD Hartkopf, A Schneeweiss, J Lermann, Tanja Fehm, Diana Lüftner, H-C Kolberg, MP Lux, M. W. Beckmann, PA Fasching, Markus Wallwiener, Wolfgang Janni, M Geberth, Hans Tesch, W Abenhardt, M Untch, C Kurbacher, C. Thomssen, V Müller, D. Wallwiener, C Hielscher, Rachel Wuerstlein, J Ettl, Friedrich Overkamp, J Huober, Bernhard Volz, P Wimberger
Publikováno v:
Cancer Research. 79:P6-17
Background Studies leading to the approval of trastuzumab emtansine (T-DM1) have been conducted without pertuzumab as previous therapy. Therefore data about patient characteristics and the efficacy of T-DM1 after a treatment with pertuzumab is scarce
Autor:
L Haeberle, Wolfgang Janni, Markus Wallwiener, M. W. Beckmann, Bernhard Volz, Tanja Fehm, Rachel Wuerstlein, J Huober, MP Lux, V Müller, AD Hartkopf, C Thomssen, Friedrich Overkamp, Christian M. Kurbacher, F-A Taran, C Hielscher, M Geberth, J Lermann, P Wimberger, W Abenhardt, Michael Untch, DI Lueftner, Andreas Schneeweiss, PA Fasching, Sara Y. Brucker, D. Wallwiener, P. Hadji, H-C Kolberg, Erik Belleville, J Ettl, H Tesch
Publikováno v:
Cancer Research. 79:P6-17
Purpose: This analysis describes comprehensive real-world data concerning the use of anti-HER2 therapies in HER2 positive metastatic breast cancer (MBC). Specifically, it describes the therapy patterns of treatments with trastuzumab (TZM), pertuzumab
Autor:
Steffi Busch, C Hielscher, Jörg Schilling, Christian M. Kurbacher, Claus Hanusch, Meinolf Karthaus
Publikováno v:
Cancer Research. 79:P1-11
Background The oral fixed dose combination of netupitant and palonosetron NEPA has been approved for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in cancer patients receiving cisplatin-based highly emetogenic (H
Autor:
Erik Belleville, Sara Y. Brucker, Johannes Ettl, H-C Kolberg, Friedrich Overkamp, PA Fasching, D. Wallwiener, P. Hadji, C Hielscher, Lothar Haeberle, D Lueftner, Andreas D. Hartkopf, Volkmar Mueller, Markus Wallwiener, Bernhard Volz, M. W. Beckmann, Wolfgang Janni, Hans Tesch, Naiba Nabieva, P Wimberger, Tanja Fehm, Anna-Lisa Brandl, Florin-Andrei Taran, Andreas Schneeweiss, Michael P. Lux
Publikováno v:
Cancer Research. 78:P6-11
Background: Improved progression-free survival is considered as treatment goal for patients with metastatic breast cancer (MBC) since it is assumed to delay or prevent deterioration of quality of life.Aim of our analysis was to examine the influence
Autor:
Jens Huober, M Wallwiener, Lothar Haeberle, MP Lux, F-A Taran, C Hielscher, Wolfgang Janni, P Wimberger, Rachel Wuerstlein, Bernhard Volz, W Abenhardt, N. Fersis, Friedrich Overkamp, Sara Y. Brucker, D. Wallwiener, Erik Belleville, H-C Kolberg, Volkmar Mueller, P. Hadji, M Geberth, C. Thomssen, Tanja Fehm, Andreas Schneeweiss, H Tesch, D Lueftner, Michael Untch, Peter A. Fasching, M. W. Beckmann, J Ettl, C Kurbacher, AD Hartkopf
Publikováno v:
Cancer Research. 78:P3-11
Background For breast cancer patients with metastases which are not life threatening national and international guidelines recommend the exhaustion of all antihormonal therapeutic options before recommending chemotherapy. In Germany up to now only ev